Skip to main content

Table 1 Baseline clinical characteristics according to HBcAb status in HBsAg-negative DLBCL patients

From: Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

Characteristic HBcAb-negative [cases (%)] HBcAb-positive [cases (%)] P value
Total 110 55  
Sex    0.434
 Male 67 (60.9) 30 (54.5)
 Female 43 (39.1) 25 (45.5)
ECOG PS    0.525
 0–1 96 (87.3) 46 (83.6)
 ≥2 14 (12.7) 9 (16.4)
Bulky mass    0.619
 Yes 28 (25.5) 16 (29.1)
 No 82 (74.5) 39 (70.9)
B symptoms    0.448
 − 80 (72.7) 43 (78.2)
 + 30 (27.3) 12 (21.8)
Ann Arbor stage    0.698
 I–II 52 (47.3) 28 (50.9)
 III-IV 57 (51.8) 27 (49.1)
Liver involvement    0.720
 − 104 (94.5) 53 (96.4)
 + 6 (5.5) 2 (3.6)
IPI score    0.851
 0–1 48 (43.6) 21 (38.2)
 2 28 (25.4) 17 (30.9)
 3 23 (20.9) 11 (20.0)
 4-5 10 (9.1) 6 (10.9)
ALT    0.874
 ≤40 U/L 95 (86.4) 47 (85.5)
 >40 U/L 15 (13.6) 8 (14.5)
AST    0.863
 ≤45 U/L 97 (88.2) 49 (89.1)
 >45 U/L 13 (11.8) 6 (10.9)
TB    0.852
 ≤20.5 μmol/L 99 (90.0) 50 (90.9)
 >20.5 μmol/L 11 (10.0) 5 (9.1)
LDH    0.910
 ≤245 U/mL 67 (60.9) 33 (60.0)
 >245 U/mL 43 (39.1) 22 (40.0)
HBsAb    <0.001
 – 82 (74.5) 3 (5.5)
 + 28 (25.5) 52 (94.5)
HBeAb    0.251
 – 102 (92.7) 48 (87.3)
 + 8 (7.3) 7 (12.7)
  1. HBcAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, international prognostic index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TB, total bilirubin; LDH, lactate dehydrogenase; HBsAb, hepatitis B surface antibody; HBeAb, hepatitis B e antibody. The information of Ann Arbor stage and IPI were available for 164 patients.